Literature DB >> 10525392

Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.

G Hornreich1, U Beller, O Lavie, P Renbaum, Y Cohen, E Levy-Lahad.   

Abstract

OBJECTIVES: Type II endometrial carcinomas are estrogen-independent and have adverse histologic features and a substantially poorer prognosis. No risk factors have been identified. Interestingly, there is a striking clinical and histopathological similarity between serous papillary carcinomas of the ovary (OSPC), endometrium, and peritoneal cavity, suggesting a common oncogenic mechanism. Several common molecular alterations were found using molecular comparative analysis of OSPC and uterine serous papillary carcinoma (USPC). Germline mutations in the BRCA1 tumor suppressor gene predispose to breast and ovarian cancer but no association with sporadic endometrial cancer has been found. A family of Ashkenazi Jewish origin, in which one sister was first diagnosed with USPC and the second diagnosed with OSPC, led to the hypothesis that a BRCA mutation may contribute to USPC.
METHODS: Genomic DNA from both patients as well as two unaffected siblings was analyzed for the three mutations common in Ashkenazi Jews. Loss of heterozygosity (LOH) analysis was performed on DNA extracted from USPC tumor tissue.
RESULTS: Both affected sisters tested positive for BRCA1 5382insC germline mutation. LOH analysis confirmed the results.
CONCLUSIONS: We present a breast-ovarian cancer family including two sisters with advanced serous papillary carcinomas of endometrial and ovarian origins, carrying the same BRCA1 mutation (5382insC). LOH analysis on USPC tumor DNA showed loss of the wild-type allele, suggesting a causal relationship between the germline BRCA1 mutation and USPC. We believe a study examining BRCA1 mutations in a large cohort of women with this high-risk endometrial carcinoma is warranted. A positive finding may have implications for surveillance and prophylactic surgery in carriers of BRCA1 mutations. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10525392     DOI: 10.1006/gyno.1999.5568

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

Authors:  Kathryn P Pennington; Tom Walsh; Ming Lee; Christopher Pennil; Akiva P Novetsky; Kathy J Agnew; Anne Thornton; Rochelle Garcia; David Mutch; Mary-Claire King; Paul Goodfellow; Elizabeth M Swisher
Journal:  Cancer       Date:  2012-07-18       Impact factor: 6.860

Review 2.  Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.

Authors:  Murray Joseph Casey; Agnes B Colanta
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

3.  Cancer susceptibility gene mutations in type I and II endometrial cancer.

Authors:  Beverly Long; Jenna Lilyquist; Amy Weaver; Chunling Hu; Rohan Gnanaolivu; Kun Y Lee; Steven N Hart; Eric C Polley; Jamie N Bakkum-Gamez; Fergus J Couch; Sean C Dowdy
Journal:  Gynecol Oncol       Date:  2018-10-26       Impact factor: 5.482

Review 4.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 5.  Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.

Authors:  Amanda B Spurdle; Michael A Bowman; Jannah Shamsani; Judy Kirk
Journal:  Mod Pathol       Date:  2017-04-28       Impact factor: 7.842

Review 6.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

7.  Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.

Authors:  Murray Joseph Casey; Chhanda Bewtra; Henry T Lynch; Carrie Snyder; Mark Stacy; Patrice Watson
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

8.  Controversies in the management of endometrial carcinoma: an update.

Authors:  Mohamed K Mehasseb; John A Latimer
Journal:  Obstet Gynecol Int       Date:  2012-02-16

Review 9.  Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?

Authors:  Adele Wong; Joanne Ngeow
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

10.  Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.

Authors:  R I Olivier; M van Beurden; M A C Lubsen; M A Rookus; T M Mooij; M J van de Vijver; L J van't Veer
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.